{"id":1394261,"date":"2026-05-15T07:30:00","date_gmt":"2026-05-15T05:30:00","guid":{"rendered":"https:\/\/nosaplugs.com\/sv\/blog\/mfn_news\/nosa-plugs-ab-interim-report-for-the-first-quarter-of-2026\/"},"modified":"2026-05-15T07:30:00","modified_gmt":"2026-05-15T05:30:00","slug":"nosa-plugs-ab-interim-report-for-the-first-quarter-of-2026","status":"publish","type":"mfn_news","link":"https:\/\/nosaplugs.com\/sv\/blog\/mfn_news\/nosa-plugs-ab-interim-report-for-the-first-quarter-of-2026\/","title":{"rendered":"Nosa Plugs AB Interim Report for the First Quarter of 2026"},"content":{"rendered":"
\n

This English version is a translation of the Swedish quartaly report of Nosa Plugs AB (publ). In the event of any<\/em>
discrepancies, the Swedish version shall prevail.<\/em><\/p>\n

CEO statement<\/strong><\/p>\n

The year has started at a high pace, and we continue to exceed our sales targets for our two largest products \u2013 Odor Control and Nozoil.<\/p>\n

The quarter amounted to net sales of SEK 8.2 million, representing an increase of 94 per cent compared with the previous year. At the same time, we have initiated the margin improvement journey for Nozoil, resulting in an increase in total gross margin from 58 per cent in the previous quarter to 63 per cent in the current quarter. EBITDA was in line with our targets.
\u00a0
Nozoil<\/strong>
Sales of Nozoil continue to increase steadily, primarily in Germany, where we continue to expand our reach to additional pharmacies each day. Somewhat unexpectedly, the seasonal effect has been less pronounced than anticipated, and we have not seen any decline in volumes towards the end of the quarter. It is still too early to draw any firm conclusions, but we interpret the signals from pharmacies as indicating that an increasing number of customers are purchasing the product to relieve allergy-related symptoms.<\/p>\n

We have now initiated the process of bringing the technical file for Nozoil in-house. This means that, in the near future, we will fully own the product\u2019s technical intellectual property, which has previously been owned by the manufacturer. The process will result in increased development expenses during the first nine months of the year, but is thereafter expected to contribute to an improved gross margin.<\/p>\n

Following the end of the quarter, we launched Nozoil together with the remaining consumer product portfolio in the French market. This marks a further step in the European rollout of the consumer portfolio, with strengthened gross margins in our key markets.
\u00a0
Odor control<\/strong>
We are once again seeing strong growth across all markets. The Nordic region has returned to the levels we have maintained over recent years, and Norway is developing in line with plan. A key factor behind this success has been the implementation of geo-fenced marketing on social media platforms, enabling us to reach the right target audience more effectively within defined geographical areas. This makes our advertising more relevant to end customers and, consequently, more cost-efficient for us.
At present, a strong focus is placed on the French market, where new procurement agreements have entered into force while we continue to work towards securing listings in additional regions.
\u00a0
Drug Delivery becomes Cerevia<\/strong>
The working name \u201cDrug Delivery\u201d is now a thing of the past, and the product is today marketed under the name \u201cCerevia\u201d. The name directly indicates an effect on the brain and the central nervous system, and the decision was made to demonstrate that the product is now a commercially viable technology \u2013 ready for partnerships.<\/p>\n

There has been limited news flow for some time, but this does not mean that we have not continued our work with full commitment. Two companies are still evaluating our technology. Unfortunately, these evaluation processes are progressing far more slowly than we had hoped, and it is frustrating that we are unable to accelerate the process further despite our ongoing efforts.<\/p>\n

In parallel, we are working to identify additional patented molecules and evaluate these in order to present the resulting data to more pharmaceutical companies. We also continue to strengthen the pharmacokinetic data demonstrating how the molecules are absorbed and distributed within the body.<\/p>\n

Outlook<\/strong>
In relation to Cerevia, we will participate in BIO International in the United States during June. It is one of the world\u2019s largest conferences for pharmaceutical companies, and we already have several promising meetings scheduled.<\/p>\n

In addition, we are strengthening our team with additional resources, primarily within sales and quality assurance. This is an important step in enabling us to continue growing at the rapid pace we are currently experiencing.
\u00a0
Financial Performance<\/strong>
1 January – 31 March 2026<\/p>\n